Tuesday, March 11, 2014

Talk about timing - Oxigene reports positive topline results from randomized phase 2 study of Zybrestat - stock is up over 18%!

I wrote an article yesterday about the most overpriced and underpriced biotechs.  Oxigene (OXGN) was my pick for most undervalued due to it's upcoming phase 2 results of it's lead compound, Zybrestat, to treat Ovarian cancer.   Results are out and they are communicating positive topline results; stock is up over 18% in the last few minutes of trading.  


No comments:

Post a Comment

Thank you for your contribution to BiotechInvestor.com